Barrett's Esophagus References

REFERENCES

Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2004 Apr;19(4):357-367. PMID: 15012771
Sampliner RE, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002 Aug;97(8):1888-1895. PMID: 12190150
DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005 Jan;100(1):190-200. PMID: 15654800
Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008 Mar;103(3):788-797. doi: 10.1111/j.1572-0241.2008.01835.x. PMID: 18341497
Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med. 2002 Mar;346(11):836-842. PMID: 11893796
Shalauta M, Saad R. Barrett's esophagus. Am Fam Physician. 2004 May;69(9):2113-2118. PMID: 15152957
MedWormhttp://www.medworm.com/rss/index.php/Gastroenterology/17/http://www.medworm.com/rss/medicalfeeds/specialities/Gastroenterology.xml
Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel Veterans Health Administration Department of Veterans Affairs. VHA/DoD clinical practice guideline for the management of adults with gastroesophageal reflux disease in primary care practice. http://www.guideline.gov/. Mar 2003.
American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011 Mar;140(3):1084-1091. http://www.gastro.org/practice/medical-position-statements/Barretts_MPS.pdf. Accessed 21 Feb 2014. PMID: 21376940
Booth CL, Thompson KS. Barrett's esophagus: a review of diagnostic criteria, clinical surveillance practices and new developments. J Gastrointest Oncol. 2012 Sep;3(3):232-242. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418534/. Accessed 21 Feb 2014. PMID: 22943014
Chang CY, Cook MB, Lee YC, et al. Current status of Barrett's esophagus research in Asia. J Gastroenterol Hepatol. 2011 Feb;26(2):240-246. http://pubmedcentralcanada.ca/pmcc/articles/PMC3026914/pdf/nihms256182.pdf. Accessed 21 Feb 2014. PMID: 21155883
Sharma P, Katzka D, Gupta N, et al. Quality indicators for the management of Barrett's esophagus, dysplasia and esophageal adenocarcinoma: international consensus recommendations from AGA symposium. Gastroenterology. 2015:1-24. doi: 10.1053/j.gastro.2015.08.00. Accessed 25 Aug 2015
Sollano JD, Romano RP, Ibanez-Guzman L, et al. Clinical practice guidelines on the diagnosis and treatment of gastroesophageal reflux disease (GERD). Philippine Journal of Internal Medicine. 2015 Jul-Sep;53(3):1-17. http://www.pcp.org.ph/. Accessed 02 Oct 2015
Shaheen NJ, Falk GW, Iyer PG, et al; American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol. 2016 Jan;111(1):30-50. doi: 10.1038/ajg.2015.322. Accessed 24 Oct 2016. PMID: 26526079
Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut. 2016 Sep;65(9):1402-1415. doi: 10.1136/gutjnl-2016-311715. PMID: 27261337
ASGE Standards of Practice Committee, Qumseya B, Sultan S, Bain P, et al. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. doi: 10.1016/j.gie.2019.05.012. PMID: 31439127
Sharma P, Shaheen NJ, Katzka D, et al. AGA clinical practice update on endoscopic treatment of Barrett's esophagus with dysplasia and/or early cancer: expert review. Gastroenterology. 2020 Feb;158(3):760-769. doi: 10.1053/j.gastro.2019.09.051. PMID: 31730766
Zimmerman TG. Common questions about Barrett esophagus. Am Fam Physician. 2014 Jan 15;89(2):92-98. https://www.aafp.org.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.